18F-FDG PET During Initial Therapy for Hodgkin's Lymphoma
| Cycles before PET | No. of patients | No. of patients with positive PET results | PPV (%) | NPV (%) | % EFS (no. of y) for patients with the following PET results: | Median follow-up (mo) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study | Type | Positive | Negative | Median TTF (mo) | ||||||
| Friedberg et al. (3) | Prospective | 3 | 22* | 5 | 80 | 94 | — | — | 24 | — |
| Gallamini et al. (27)† | Prospective | 2 | 61 | 10 | 90 | 98 | 10 (3) | 98 (3) | 19 | — |
| Hutchings et al. (28) | Retrospective | 2 or 3 | 85‡ | 13 | 61.5 | 94 | 46 (2), 38.5 (5) | 97 (2), 91.5 (5) | 40 | 24 if PET positive, 9 if PET negative (including MRU) |
| Hutchings et al. (25) | Prospective | 2 | 77 | 16 | 69 | 95 | 0 (2) | 96 (2) | 23 | — |
| Hutchings et al. (25) | Prospective | 4 | 64§ | 13 | 85 | 96 | 19 (2) | 96 (2) | 23 | — |
↵* Thirty-six additional patients had PET scans after therapy completion; results for 8 were positive, with PPV of 50% and NPV of 96%.
↵† Interim data.
↵‡ Nine patients had MRU; for analysis, their PET results were considered negative.
↵§ PET was also performed after therapy completion for 65 patients; results for 9 were positive, with PPV of 78% and NPV of 96%.
PPV = positive predictive value; NPV = negative predictive value; EFS = event-free survival; TTF = time to treatment failure; — = no data; MRU = minimal residual uptake. Definition of EFS variably represents freedom from relapse, progression on therapy, incomplete remission, disease-related death, or death from any cause.